We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From May 2019 to May 2024
0910 GMT - AstraZeneca's partial divestment of anti-infective treatment Synagis to Sobi follows a pattern of deals that offload "non-core" products to raise money for its pipeline of new drugs. Synagis, a treatment that prevents respiratory tract infections in infants, falls outside of AstraZeneca's focus areas of cancer, diabetes, cardiovascular medicine, and chronic respiratory conditions like asthma. Astra has sold off a string of drugs that do not fit into these areas in recent years, and plowed the proceeds into research and marketing for those that do. Astra shares are up 0.9% to GBP63.09 Tuesday morning. ( denise.roland@wsj.com ; @deniseroland) -0---Denise RolandREPORTER O: +44 (0)
(END) Dow Jones Newswires
November 13, 2018 04:25 ET (09:25 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
